StockpollyBeta
Get App
Popularity #4,600
CYCN · NASDAQ · Biotechnology

Cyclerion Therapeutics (CYCN)

Holds a suspended depression-treatment system and out-licensed sGC development rights.

$23.52
vs last close0.00 (0.00%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000002001100
Cost of revenue000000000010
Gross profit0000020011−10
622111222222
Research & development100000000110
222111222122
Selling & marketing000000000000
General & administrative222111222122
Other expenses3000000000−10
Operating income−6−2−2−1−11−1−2−1−1−3−2
000000010000
Interest income000000000000
Other non-operating income−3000000−10000
Income before tax−6−2−2−1−11−10−1−1−3−2
Net income from continuing operations−6−2−2−1−11−10−1−1−3−2
Discontinued operations1300000000000
Net income8−2−2−1−11−10−1−1−3−2
EPS, basic−$3.36−$4.76−$4.34−$3.71−$2.03$1.47−$3.92−$0.77−$2.10−$1.75−$5.32−$2.87
EPS, diluted−$3.36−$4.76−$4.34−$3.71−$2.03$1.47−$3.92−$0.77−$2.10−$1.75−$5.32−$2.87
Weighted average shares, basic200000000011
Weighted average shares, diluted200000000011
EBITDA−3−2−2−1−11−10−1−1−3−2
Depreciation & amortization000000000000
EBIT−3−2−2−1−11−10−1−1−3−2